期刊
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
卷 73, 期 10, 页码 948-953出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NEN.0000000000000114
关键词
Alzheimer disease; Amyloid imaging; Autopsy; Dementia; Diagnosis; Neuropathology; Sensitivity; Specificity; Therapy
资金
- National Institute on Aging [U01 AG016976]
- Arizona Alzheimer's Disease Core Center [P30 AG19610]
- Rush University Alzheimer's Disease Core Center [P30 AG10161]
In 2012, florbetapir (F-18) (Amyvid) received US Food and Drug Administration approval as a diagnostic agent for detecting neuritic (beta-amyloid) plaques in living patients. Although such approval is specifically not extended to the use of florbetapir as a single definitive diagnostic test for Alzheimer disease dementia (ADD), it is of considerable importance to examine its potential in this regard. To estimate the ability of florbetapir amyloid imaging to detect specified densities of postmortem-identified neuritic plaques, we used the data of Clark et al [Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study. Lancet Neurol 2012; 11: 669-78]. We then used the data of Beach et al [Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-73], derived from the National Alzheimer's Coordinating Center, to estimate the fraction of subjects who would have been called florbetapir-positive and, among these, the fraction of subjects who would also meet neuropathologic criteria for the presence of ADD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据